Sanofi-aventis Announces Update
To The European Summary Of Product Characteristics (SmPC)
For Ketek® (telithromycin)

Paris, France, March 30, 2007 – Sanofi-aventis announced today that the European Summary of Product Characteristics (SmPC) has been revised for Ketek® (telithromycin) following interactions with and review of the effectiveness and safety of this product by the European Medicines Agency (EMEA) - Committee for Medicinal Products for Human use (CHMP) earlier this year.

The CHMP concluded that the effectiveness of Ketek® has been confirmed in its approved indications in Europe, taking into account the local epidemiology of resistance and guidelines: mild to moderate community-acquired pneumonia (CAP), acute exacerbation of chronic bronchitis (AECB), acute sinusitis (AS)* and tonsillitis/pharyngitis (T/P) caused by Streptococcus pyogenes in patients of 12 years and older. However, the CHMP believed that Ketek® in AECB and AS should be used in the treatment of infections caused by bacteria that are known or suspected to be resistant to beta-lactams or macrolides and also that Ketek® in T/P should be prescribed in situations where beta-lactams are not appropriate, in countries or regions where there are high levels of resistance to macrolides.

The existing warning over the use of Ketek® in patients with myasthenia gravis, a rare autoimmune disease, has also been upgraded to a Contraindication. The revised SmPC also includes a strengthened Warning about temporary visual disturbances and transient loss of consciousness (syncope) for which a bedtime intake should be considered to reduce the impact of these side effects. Severe problems with the liver have rarely been reported with Ketek® but they do not occur more frequently than with other relevant antibiotic medicines.

Sanofi-aventis commits to undertake risks minimization measures by providing updated information to Healthcare Professionals and myasthenia gravis patient associations.

Given the increasing rates of resistance to macrolides and beta lactam antibiotics in many countries, Ketek®, when used in accordance with the updated European product information continues to be an important option in the anti-infective armamentarium and helps to satisfy a medical need.

Ketek® is currently marketed in over 50 countries. Since its launch, it is estimated that over 30 million courses of Ketek® treatment have been prescribed worldwide.

* in patients of 18 years and older.
About sanofi-aventis
Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expect,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2005. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.